First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer

Grynberg, Michaël; Bras, Anne Mayeur Le; Hesters, Laëtitia; Gallot, V.; Frydman, Nelly

doi:10.1016/j.annonc.2020.01.005

Cited by 30 publications

(12 citation statements)

References 1 publication

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it still merits our attention, reassuring obstetrical and neonatal data have also been preliminary outlined 23 , 24 . However, the competence of IVM oocytes remains poorly known, even if live births were recently reported 25 .…”

Section: Discussionmentioning

confidence: 99%

Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible

Sermondade

Grynberg

Comtet

et al. 2020

Sci Rep

View full text Add to dashboard Cite

When ovarian stimulation is unfeasible, in vitro maturation (IVM) represents an alternative option for fertility preservation (FP). This retrospective study aims to evaluate the feasibility of performing within a short time frame two IVM cycles for FP. Seventeen women with breast cancer, 18–40 years of age, having undergone 2 cycles of IVM followed by oocyte vitrification were included. Non parametric analyses were used. No difference was observed between IVM1 and IVM2 outcomes. No complication was reported. The respective contributions of IVM1 and IVM2 for the number of cryopreserved oocytes were comparable irrespective of the delay between both procedures, even when performed during the same menstrual cycle. Those findings suggest that repeating IVM cycles may constitute a safe option for increasing the number of vitrified mature oocytes for FP. These two retrievals may be performed during the same cycle, providing additional argument for a physiologic continuous recruitment during follicular development.

show abstract

Section: Discussionmentioning

confidence: 99%

Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible

Sermondade

Grynberg

Comtet

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In cancer patients, the administration of a bolus of hCG before oocyte retrieval has shown to not improve the total number of mature oocytes for cryopreservation [64]. The first livebirth following vitrification of in vitro matured oocytes harvested transvaginally demonstrates the utility of IVM in the overall strategy of female FP [85] (Fig. 1).…”

Section: Ivm For Fertility Preservationmentioning

confidence: 99%

Perspectives on the development and future of oocyte IVM in clinical practice

Vos

Grynberg

et al. 2021

J Assist Reprod Genet

105

View full text Add to dashboard Cite

Oocyte in vitro maturation (IVM) is an assisted reproductive technology designed to obtain mature oocytes following culture of immature cumulus–oocyte complexes collected from antral follicles. Although IVM has been practiced for decades and is no longer considered experimental, the uptake of IVM in clinical practice is currently limited. The purpose of this review is to ensure reproductive medicine professionals understand the appropriate use of IVM drawn from the best available evidence supporting its clinical potential and safety in selected patient groups. This group of scientists and fertility specialists, with expertise in IVM in the ART laboratory and/or clinic, explore here the development of IVM towards acquisition of a non-experimental status and, in addition, critically appraise the current and future role of IVM in human ART.

show abstract

“…Grynberg et al [44] reported the first live birth using IVM in a young woman with a diagnosis of ER-positive BC. Even if progresses in sustaining in vitro growth of human oocytes have been made, the pregnancy outcomes after IVM are still suboptimal, with lower implantation rates as compared with embryos obtained from mature oocytes [45,46].…”

Section: Alternative Optionsmentioning

confidence: 99%

Fertility preservation in endocrine responsive breast cancer: data and prejudices

Buonomoa¹,

Peccatorib²

2020

ecancer

View full text Add to dashboard Cite

Even if current guidelines suggest an early referral of young breast cancer (BC) patients to fertility preservation counselling, physicians still lack knowledge about the different available strategies. Hormonal stimulation to harvest mature oocytes is considered unsafe by many oncologists and experts in reproductive medicine, particularly in the setting of oestrogen receptor-positive BC. The aim of this mini-review is to provide an overview on the available data about this topic in order to clarify potential misunderstandings and to highlight the new trends in the oncofertility field with their pros and limitations.

show abstract

First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer

Cited by 30 publications

References 1 publication

Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible

Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible

Perspectives on the development and future of oocyte IVM in clinical practice

Fertility preservation in endocrine responsive breast cancer: data and prejudices

Contact Info

Product

Resources

About